EGFR and lung carcinoma: In contrast to chemotherapy, Keytruda® (pembrolizumab) significantly prolongs patient survival in patients with lung cancer who have high expression level of PD-L1 (PD-L1 ≥ 50%) and no EGFR or ALK mutations [3].